Skip to main content
🇺🇸 100% Domestic·Synthesized & Shipped in the USABuy 2+ Save 10%·Buy 3+ Save 15%·Buy 5+ Save 20%Free Shipping on Orders Over $200Ships from a U.S. Facility — 1–3 Day ProcessingThird-Party Tested·COAs Available on RequestResearch Grade·≥ 99% Purity Standard🇺🇸 100% Domestic·Synthesized & Shipped in the USABuy 2+ Save 10%·Buy 3+ Save 15%·Buy 5+ Save 20%Free Shipping on Orders Over $200Ships from a U.S. Facility — 1–3 Day ProcessingThird-Party Tested·COAs Available on RequestResearch Grade·≥ 99% Purity Standard
USA Synthesized & Shipped
Third-Party Lab Tested
≥99% Purity Guaranteed
Free US Shipping $200+
A
SPADIN ANALOGUE · RESEARCH HUB

PE-22-28 Research Hub — Spadin Analogue & TREK-1 Studies

PE-22-28 is a synthetic heptapeptide analogue of spadin, widely cited in research literature as a selective TREK-1 potassium-channel blocker with downstream effects on monoaminergic signalling.

What this hub covers

  • Spadin-derived heptapeptide structure
  • TREK-1 (KCNK2) potassium-channel blockade
  • Downstream monoaminergic signalling in published models
  • Reconstitution and storage

PE-22-28 research articles

Nootropics Research

PE-22-28 Research Overview

PE-22-28 is a synthetic hexapeptide fragment of spadin — the endogenous TREK-1 potassium channel antagonist derived from the propeptide of the neurotensin receptor 3 (NTSR3/sortilin) — studied for rapid-onset antidepressant effects, hippocampal neurogenesis, BDNF upregulation, and serotonergic system modulation in preclinical depression and anxiety research models.

Read article →

PE-22-28 research FAQ

What is PE-22-28?
PE-22-28 is a synthetic heptapeptide analogue of spadin, widely cited in research literature as a selective TREK-1 (KCNK2) potassium-channel blocker.

All content on this hub is provided strictly for laboratory research purposes. Compounds listed are not for human or veterinary consumption. See our research-use disclosure for full terms.